Director: Prof. Dr. Gert-Jan van Ommen
Gert-Jan van Ommen has been involved in genomics for >20 years. He was head of the Department of Human Genetics at the Leiden University Medical Center (Leiden, the Netherlands) for 20 years (until September 2012). He is involved in the development and application of genome research and diagnostic technology for disease study, diagnosis, therapy and prevention, including the societal aspects of genetic advances.
He has a broad focus on all that is genetic, but particularly in neuromuscular and neurodegenerative diseases with a focus on Duchenne Muscular Dystrophy and Huntington Disease. The antisense-mediated exon skipping therapy approach for Duchenne Muscular Dystrophy was pioneered in the department under his supervision, and brought into a first clinical trial in the LUMC on his initiative and guidance.

He has been president of the Human Genome Organization (HUGO), co-founder and on the scientific advisory boards for BBMRI, coordinator of BBMRI-NL, co-coordinator of NeurOmics, and country coordinator of the Joint Action project “Orphanet Europe”. Furthermore, he is founder of the Leiden Genome Technology Center (LGTC), a principal genomics facility in the Netherlands.

Programme manager: Dr. Petra van Overveld
Petra van Overveld is responsible for the operational and organisational aspects of the consortium. This includes supervision of the CMSB research projects in close collaboration with the principal investigators and project leaders, writing scientific reports, organisation of symposia, and communicating the centre’s results to a broader audience.

Petra completed her biology degree at Leiden University cum laude in December 1999. She performed her PhD research at the Department of Human Genetics at the Leiden University Medical Center (LUMC, the Netherlands) and defended her thesis “Genetic and epigenetic studies of the FSHD-associated D4Z4 repeat” in April 2005. Subsequently, she worked as a postdoctoral researcher on a project on epithelial-mesenchymal transition and osteomimicry in bone metastasis from prostate carcinoma at the LUMC Department of Urology until August 2008. From September 2008 onwards, she works as programme manager for the CMSB.